Premium
Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors
Author(s) -
Hellmann K.,
Murkin Gillian E.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197410)34:4<1033::aid-cncr2820340412>3.0.co;2-0
Subject(s) - medicine , radiation therapy , cyclophosphamide , methotrexate , fluorouracil , toxicity , pharmacology , chemotherapy , cancer research , oncology
ICRF 159, an antimitotic agent that increases the antitumor activity of most antineoplastic drugs, has now also been shown to potentiate radiotherapy. This potentiation has been obtained without concommitant increase in toxicity. The resulting therapeutic synergism is greater with ICRF 159 than with equiactive doses of 5‐fluorouracil, methotrexate, hydroxyurea, or cyclophosphamide when they are combined with radiation. Timing of administration of ICRF 159 in relation to radiotherapy is a significant factor in determining the results obtained.